In an attempt to elucidate the role of methylation in parental imprinting at the IGF-II gene locus, for which imprinting has already been described in the mouse; we undertook an allele specific methylation study of the human IGF-II gene (mapped to 1lpl5.5) in a control population and in patients with Beckwith-Wiedemann syndrome.
methylation study of the human IGF-II gene (mapped to 1lpl5.5) in a control population and in patients with Beckwith-Wiedemann syndrome.
In control leucocyte DNA (16 unrelated adults and eight families), the maternal allele of the IGF-II gene was specifically hypomethylated, whereas no such allele specific methylation was found for either the insulin or the calcitonin genes which are located in llpl5.5 and lpl5.1, respectively. Furthermore, the IGF-II gene specific hypomethylation was localised on the 5' portion of exon 9. In the patients with Beckwith-Wiedemann syndrome in which the IGF-II gene is thought to be involved and where paternal isodisomy has been described, hypomethylation of the maternal allele was conserved in leucocyte DNA, but abnormal methylation was detected in malformed tissues where the paternal allele was also demethylated. Some specific mechanism linked to methylation therefore seems to be involved in the pathogenesis of Beckwith-Wiedemann syndrome.
(J7 Med Genet 1993; 30:353-62) Various family studies have indicated that there is a link between Beckwith-Wiedemann syndrome and the llpl5 region of chromosome 1112 which also carries the insulin-like growth factor II (IGF-II) gene.3 This syndrome causes childhood malformation and is characterised by a number of congenital disorders (neonatal gigantism, omphalocele, macroglossia, visceromegaly, hemihypertrophy, and neonatal hypoglycaemia) and is frequently associated with tumours (nephroblastoma, adrenocortical carcinoma, neuroblastoma, and hepatoblastoma).45 Expression of IGF mRNA has been seen to increase in a variety of tumours '5 and IGF-II is known to play a pivotal role in cell proliferation'6 and embryonic development. ' investigated with no signs of Beckwith-Wiedemann syndrome, but with embryonic tumours often associated with the syndrome, such as adrenocortical carcinoma (P24), neuroblastoma (patients P25 and P26), and nephroblastoma (P27).
Family analysis was possible in 14 cases,  both parents of P1, P3, P5, P6, P7, P9, PIO,  P13, P14, P16, P19, P20 , and only the mothers of patients P2 and P24.
Controls
The control population has been described previously'5: 16 unrelated subjects and eight families (including 10 children and 16 parents) were studied. the IGF-II cDNA was used as probe. Num A specific profile was detected with AvaII for the IGF-II gene in some tissues where DNA was demethylated and the 1 6 kb fragment was cleaved to a 05 kb fragment, as previously described'5 ( fig 1) .
For dot blot analysis, RNA samples were dotted onto a Hybond-N membrane (Amersham, England) using a Hybri-dot (BRL, USA) apparatus as previously described. '5 For Northern blot analysis, denatured total RNA was loaded onto 1-2% agarose-formaldehyde gels for electrophoresis, then transferred to Hybond-N membranes (Amersham, England), as previously reported. '5 striction The blots were hybridised according to the gment manufacturer's instructions with 3 x 10 cpm/ gth ml of 32p labelled probe, then washed twice '-II at room temperature and once at 65°C, each ed.
for 20 minutes, in 0-1 x SSPE (1 x SSPE t 001 mol/l NaH2PO4, pH 68, 0001 mol/l 'hern EDTA-Na2, 0 15 mol/l NaCl) and 0 1% SDS, before being exposed to x ray film (Curix RP1- Figure 4 Southern blot analysis of control leucocyte DNA digested with AvaII, using the IGF-II cDNA probe (exons 7, 8, 9) and exon 7 (A) or exon 9 (B) specific probes. (1) Homozygote for the 0 9 kb fragment, (2) homozygote for the 1 1 kb fragment, (3) 4 2-2 kb IGF-II mRNAs were detectable by Northern blot analysis (data not shown).
In the two samples of tumour tissue available, IGF-II mRNA expression could not be measured in the nephroblastoma of P1, who was undergoing chemotherapy at the time of surgery (data not shown), but in the adrenocortical carcinoma of P24, who was not under chemotherapy, extremely high levels of IGF-II mRNA expression were found ( fig 7C) .
ALLELE SPECIFIC METHYLATION IN PATIENTS WITH BECKWITH-WIEDEMANN SYNDROME
In order to determine whether allele specific methylation of leucocyte DNA may be linked to the Beckwith-Wiedemann syndrome, double digestion experiments were done and comparisons made with the control population. This type of analysis was possible only for subjects with heterozygous profiles for AvaII for the IGF-II gene. In 11 of these patients (P1, P3C1, P9, P11, P13, P15, P16C1, P18, P19, P21, P23), the patterns were similar to those for the control population, indicating that only one allele was hypomethylated (data not shown). In only one case (P2) did both alleles remain methylated (fig 8) . In the five informative families of Beckwith-Wiedemann syndrome patients (P1, P2, P3, P13, and P19) specific hypomethylation was always found for the maternal allele (data not shown), as had leucocyte DNA still exhibited allele specific hypomethylation, only the 1 1 kb allele in P9 or the 0 9 kb allele in P13 being demethylated (fig 9) . For P24, without Beckwith-Wiede-" WI~m ann syndrome, both alleles of the adrenocortical carcinoma DNA were hypomethylated (fig 9) . These preliminary findings for DNA methylation in the tissues of four informative subjects showed a difference between leucocyte and tissue DNA in patients with Beckwith-Wiedemann syndrome and the patient with an embryonic tumour, whereas allele specific demethylation in control tissues (placenta, peritumoral adult kidney tissue) was similar to that in control leucocyte DNA (data not shown). previously been observed for the control population.
None of the patients or families investigated for the insulin and calcitonin genes showed any allele specific demethylation at least in the region of the polymorphic fragments. Here, too, the patterns were the same as those for the control population: partial demethylation of both alleles for the insulin gene and total demethylation of both alleles for the calcitonin gene (data not shown).
Where possible, tissue samples from informative subjects were also analysed (tongue samples from P1, P9, P13 with macroglossia, and tumour samples from P1 and P24), as shown in fig 6 . For P1, IGF-II DNA demethylation was evident in tongue and tumour DNA (as indicated by the presence of the 0 8, 0 7, and 0 3 kb fragments, fig 9) . However, the parental origin of the demethylated alleles could not be confirmed because of the extensive disproportion of the alleles (fig 6) . For 9 and is associated with expression of the paternal allele. This, as DeChiara et all8 proposed, may reflect negative imprinting, expression of a specific trans acting repressor inhibiting expression of the maternal, and thereby allowing expression of the paternal, allele.
We also examined the possibility of genetic abnormalities accounting for the BeckwithWiedemann syndrome. Southern blotting experiments using enzymes which show RFLPs showed that in these patients (table 1) no major chromosomal anomalies (like deletion or amplification) occurred in the lp 15 region.
Loss of heterozygosity has been described in tumours where the short arm of chromosome 11 (1 l pl3-ll pl 5) is involved,33 and particularly in Wilms' tumour.34 35 Henry et al 36 reported increased leucocyte homozygosity in patients with the Beckwith-Wiedemann syndrome as compared to controls, but our findings do not support this, as we found the same frequency of homozygosity in the two groups37 (tables 3 and 4). This discrepancy may be explained by the fact that some apparent allele losses in fact reflect mosaics with grossly disproportionate alleles, which simulate homozygosity in some patients (as in patient 1, fig 6) . Among the 'complete' Beckwith-Wiedemann syndrome patients examined in this study, three (P1, P3C1, P9) out of 15 unrelated subjects (20%) (and four out of 16 when including P3C2) exhibited total allele loss or marked disproportion, and in all of them the maternal allele was lost (or very diminished) making duplication of the paternal allele possible. Uniparental disomy is probably only one of the mechanisms that accounts for BeckwithWiedemann syndrome. Among the cases of paternal isodisomy (P1, P3C1, P9), two out of three unrelated children developed tumours (66%). A malignant tumour rate of 7 5% has been reported for Beckwith-Wiedemann syndrome. 5 The high rate found in cases of uniparental disomy (with a disproportionate pattern) could be important in genetic counselling as regards the risk of tumour in Beckwith-Wiedemann patients. Nevertheless, uniparental disomy has also been seen in nontumoral tissue (enlarged tongue and leucocytes), which means that allele loss is not always accompanied by tumour formation in these particular tissues37 (this study). For two patients (P1 and P9), we were able to show that the mosaic disomy was limited to the distal 1 Ip region (calcitonin not included). The presence of disproportionate allele intensities was probably the result of mosaicism for two types of cell, the normal (with normal heterozygote DNA) and the paternal isodisomy cells. This therefore concerns a post-zygotic event, with mitotic recombination, and indicates a low recurrence risk for a second child in a Beckwith-Wiedemann syndrome family. It also throws some light on the genetic mechanism involved. The recurrence of somatic mosaicism in the two sibs (P3C1 and P3C2) was highly improbable and suggests that an abnormal paternal 1 ipi5 chromosome was transmitted.
As in the control population, allele specificity of IGF-II gene methylation was observed in leucocyte DNA of patients with BeckwithWiedemann syndrome. Hypomethylation of the maternal allele and methylation of the paternal allele were seen in both groups. In only one case, P2, were both constitutive leucocyte alleles abnormally methylated, whereas insulin and calcitonin gene methylation resembled that of normal controls. Here, both IGF-II alleles could have been submitted to similar paternal imprinting, suggesting a mechanism different from loss of the maternal allele with paternal duplication.
Tissue (tongue or tumour) DNA methylation in patients with Beckwith-Wiedemann syndrome proved to be different from leucocyte DNA methylation. In these patients the paternal allele of the IGF-II gene was demethylated, whether or not loss of heterozygosity had occurred. The abnormal paternal allele methylation may therefore be specific to children with Beckwith-Wiedemann syndrome and embryonic tumours.
Our study indicates that there is a link at the level of the adult human IGF-II gene between methylation and differential parental imprinting. It may be that methylation is involved in uniparental disomy and hence in the pathogenesis of Beckwith-Wiedemann syndrome. Finally, the exon 9 region of the IGF-II gene, where parental allele specific methylation is found, may play a role in regulating IGF-II gene expression.
